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Background. It has been suggested that vaginal colonization with lactobacilli may reduce the risk of vulvovaginal candidiasis (VVC), but supporting data are limited. Our objective was to determine the relationship between vaginal bacterial flora and VVC.
Methods. We conducted a prospective cohort analysis that involved 151 Kenyan sex workers. At monthly follow-up visits, VVC was defined as the presence of yeast buds, pseudohyphae, or both on a wet preparation (including potassium hydroxide preparation) of vaginal secretions. Generalized estimating equations were used to identify correlates of VVC.
Results. Participants returned for a median of 12 visits (interquartile range, 11-12 visits). VVC was identified at 162 visits, including 26 involving symptomatic VVC. Bacterial vaginosis was associated with fewer episodes of VVC (adjusted odds ratio [ Conclusions. Contrary to the commonly posited hypothesis that vaginal Lactobacillus colonization has a protective effect, we found that such colonization was associated with a nearly 4-fold increase in the likelihood of symptomatic VVC.
Vulvovaginal candidiasis (VVC) affects up to 75% of reproductive-age women at least once [1] . Nearly half will experience 1 recurrences, and 5%-8% have multiple episodes each year. In addition to discomfort and the costs associated with medication and health care visits, several prospective studies have suggested that VVC may increase a woman's risk of becoming infected with human immunodeficiency virus type 1 (HIV-1) [2] [3] [4] [5] .
Although not all studies have found this association [6, 7] , a meta-analysis published in 2001 also concluded that vaginal yeast infections are associated with a 2-fold increase in the risk of HIV-1 acquisition [8] . Because of the high prevalence of this condition, VVC could contribute substantially to the population-level risk of HIV-1 infection [9] .
Numerous risk factors for VVC have been identified, but fundamental questions about the pathogenesis of this condition remain unanswered [10] . It has been suggested that normal vaginal flora, consisting predominantly of Lactobacillus species, may protect against the development of VVC, but there are limited data to support this hypothesis [11, 12] . The objective of this prospective study, which was conducted in a population of Kenyan women at increased risk for HIV-1 infection, was to examine correlates of VVC and of the subset of cases of symptomatic VVC. We focused particular attention on the dynamic relationship between vaginal bacterial flora and vaginal yeast.
SUBJECTS, MATERIALS, AND METHODS

Population and Procedures.
We recently completed a randomized trial of periodic presumptive treatment for vaginal infections [13] . Women in the study were ran-domized to receive monthly oral metronidazole plus fluconazole or identical metronidazole placebo and fluconazole placebo capsules. The analyses presented here focus on women who were randomized to receive placebo. Detailed methods have been presented elsewhere [13] . In brief, HIV-1-seronegative sex workers 18 -45 years old who attended a municipal clinic in Mombasa, Kenya, were eligible to enroll if they were not pregnant and did not currently have symptoms of vulvovaginal pruritis or abnormal vaginal discharge. At baseline and at monthly follow-up visits, women completed an interview to collect information about recent sexual behavior and genital symptoms. Medication use was recorded. To facilitate accurate ascertainment of medication use, women were encouraged to return to the clinic between scheduled visits if they required outpatient evaluation for any reason. Treatment, including medications if indicated, was provided at no cost. Risk reduction counseling was provided at each visit.
At monthly visits, a genital examination that included a speculum-aided pelvic examination was performed. Trained study clinicians identified vulvitis on the basis of vulvar erythema and edema. Specimens were collected for laboratory diagnosis of genital tract infections, a pregnancy test was performed on a urine sample, and blood was collected for HIV-1 serological testing.
Women who reported vulvovaginal pruritis or abnormal vaginal discharge during follow-up were treated syndromically with metronidazole, 2 g as a single dose, plus 200-mg clotrimazole vaginal suppositories nightly for 3 nights. Because of the time required to process specimens, participants were invited to return for their laboratory results 1 week after each examination. These results were used to guide additional treatment for sexually transmitted infections, including Neisseria gonorrhoeae infection, microscopic cervicitis, and Trichomonas vaginalis infection, in accordance with World Health Organization and Kenya Ministry of Health Guidelines [14] . Asymptomatic VVC and asymptomatic bacterial vaginosis (BV) were not treated, as there is currently no clear indication for treatment of these conditions in nonpregnant women. Participants in the trial were asked to return for a total of 12 monthly follow-up visits. Participation was discontinued if they became pregnant or became seropositive for HIV-1. This study was approved by the ethical review committees at Kenyatta National Hospital and the University of Washington. All participants provided written informed consent.
Laboratory methods. Screening for HIV-1 infection was performed using an enzyme-linked immunosorbent assay (ELISA [Detect-HIV; BioChem ImmunoSystems]). Positive samples were confirmed using a second ELISA (Recombigen, Cambridge Biotech; or Vironostika, BioMérieux) [15] . Urine pregnancy testing was performed using a rapid ␤-hCG test (Plasmatec Laboratory Products).
A saline wet mount of vaginal secretions was examined microscopically for the presence of budding yeast or pseudohyphae and for T. vaginalis. A drop of 10% potassium hydroxide was added, and the slide was examined a second time for the presence of budding yeast or pseudohyphae. Women were classified as having VVC if fungal elements were observed on either the wet mount or the potassium hydroxide preparation. We defined symptomatic VVC as the presence of fungal elements in combination with 1 genital signs or symptoms suggestive of vaginitis, (7), and norfloxacin (6) . Other oral antibacterials, prescribed Ͻ5 times each, included erythromycin, benzathine penicillin, amoxicillin with clavulanate, and levofloxacin.
i There were 20 prescriptions for clotrimazole vaginal pessaries and 2 prescriptions for nystatin vaginal pessaries. (7), and norfloxacin (6). Other oral antibacterials, prescribed Ͻ5 times each, included erythromycin, benzathine penicillin, amoxicillin with clavulanate, and levofloxacin.
i There were 20 prescriptions for clotrimazole vaginal pessaries and 2 prescriptions for nystatin vaginal pessaries.
including vulvitis, vulvovaginal pruritis, or abnormal vaginal discharge. Gram-stained slides of vaginal secretions were evaluated for BV according to microscopic criteria [16] . Endocervical secretions were also Gram stained and examined microscopically. Polymorphonuclear leukocytes (PMN) were enumerated in 3 nonadjacent high-power fields, and the average cervical PMN count was calculated.
Lactobacillus culture was performed on Rogosa agar (Difco TM; Becton Dickinson), and production of hydrogen peroxide (H 2 O 2 ) was assessed by subculture on tetramethylbenzadine agar with horseradish peroxidase [17] . Culture to identify T. vaginalis was performed in Diamond's modified medium, and culture to identify N. gonorrhoeae was performed on modified Thayer-Martin medium.
Statistical methods. Analyses were performed using SPSS (version 15; SPSS) and S-Plus 2000 (Mathsoft). All women randomized to the placebo arm of the trial were considered eligible. The primary end points were VVC (asymptomatic or symptomatic) and the subset of cases of symptomatic VVC. Separate analyses for each end point were performed using generalized estimating equations. This technique allows adjustment for the correlation between multiple events in an individual. Variables associated with the outcome of interest on univariate analysis (P р .10) were included in the multivariate models. Collinearity was evaluated and addressed in all multivariate models. The Wald statistic was used to determine the overall statistical significance for variables with multiple categories (e.g., different age group strata).
As in prior analyses [18] , we assumed a window of 85 days to capture the extended effect after discontinuation of a hormonal contraceptive method (70 days of persistent effect for hormonal contraception after discontinuation plus 15 days for the time from acquisition of a vaginal yeast infection to detection at a clinic visit, assuming acquisition occurred at the midpoint between monthly visits). Antimicrobials were modeled to have an effect for 60 days after the date on which they were prescribed. The effect window for previous identification of fungal elements on microscopy as a predictor of symptomatic VVC was also set at 60 days, but excluded the day of the analysis visit because the presence of budding yeast, pseudohyphae, or both was required for the diagnosis of symptomatic VVC. We initially examined the effects of BV and Lactobacillus colonization using a 60-day effect window. However, the effect of these exposures on VVC and symptomatic VVC appeared to be related primarily to their presence at the time of the visit during which yeast was detected. Thus, our final analyses were based on the presence of BV and Lactobacillus at the analysis visit. We also evaluated Lactobacillus status stratified by the isolates' ability to produce H 2 O 2 . Because the effect did not differ when H 2 O 2 -producing and non-H 2 O 2 -producing strains were compared, we combined Lactobacillus culture results in our final analyses.
RESULTS
From May 2003 through November 2005
, there were 310 women enrolled in the trial of periodic presumptive treatment for vaginal infections [13] . Of the 155 women randomized to the placebo arm, 151 returned for 1 follow-up visit at which they remained HIV-1 seronegative. These 151 women are included in the analyses presented here. They returned for a median of 12 visits (interquartile range [IQR], 11-12 visits), and the median interval between visits was 30 days (IQR, 28 -35 days) . Overall, the women accrued 153 person-years of follow-up over 1570 visits, representing 90% of expected follow-up visits.
The baseline clinical and demographic characteristics of the 151 sex workers are presented in table 1. The median age of participants was 32 years (IQR, 27-39 years). They reported a relatively low frequency of intercourse (median, 1 episode [IQR, 0 -2 episodes]) during the preceding week. Only 5 (3.3%) of the women reported any history of oral-vaginal contact, and none reported a history of anal intercourse. Although the women denied symptoms of vulvovaginal pruritis or abnormal discharge at enrollment, the microscopic criteria used for examination of samples indicated that 15 (9.9%) had VVC and 56 (37.1%) had BV.
Correlates of VVC. Vulvovaginal candidiasis was identified at 162 (10.3%) of 1570 follow-up visits (incidence, 106 visits with VVC per 100 woman-years). This total included 71 women who had 1 visits with VVC (median, 2 episodes [IQR, 1-3 episodes]). Correlates of VVC are presented in table 2. On univariate analysis, women with BV were significantly less likely to have VVC. This relationship remained statistically significant after adjustment for potential confounding factors. In addition, longer duration of sex work was associated with significantly lower risk for VVC in the multivariate analysis.
Correlates of symptomatic VVC. Symptomatic VVC was identified at 26 (1.7%) of 1570 follow-up visits (incidence, 17 visits with symptomatic VVC per 100 woman-years). These 26 episodes occurred in 16 women (median, 1 episode [IQR, 1-2 episodes]). One woman had 3 consecutive visits with symptomatic VVC, and another had 2. The remainder were either single episodes of symptomatic VVC for individual women or 2 episodes separated by 1 or more visits without symptomatic VVC.
Of 26 visits at which symptomatic VVC was identified, the signs and symptoms included vulvitis alone at 3 (11.5%) visits, vulvovaginal pruritis alone at 11 (42.3%), abnormal vaginal discharge alone at 6 (23.1%), vulvitis with vulvovaginal pruritis at 3 (11.5%), and vulvovaginal pruritis with abnormal vaginal discharge at 3 (11.5%). Correlates of symptomatic VVC are presented in table 3. On univariate analysis, women were significantly more likely to develop symptomatic VVC if they had had VVC identified during the past 60 days (regardless of the presence or absence of symptoms). There was also an increased risk of symptomatic VVC in women who had concurrent vaginal Lactobacillus colonization, although this association did not reach statistical significance. The findings were similar after adjustment for potential confounding factors.
Of the 26 episodes of symptomatic VVC diagnosed on the basis of microscopic detection of budding yeast or pseudohyphae in combination with symptoms or signs of vulvitis, vulvovaginal pruritis, or abnormal vaginal discharge, 7 (26.9%) occurred at visits with concurrent BV. Because the symptoms could have been related to BV rather than VVC, we repeated the analysis excluding these cases. In this analysis, prior identification of VVC (aOR, 4.06 [95% CI, 1.12-14.74]) and concurrent Lactobacillus colonization (aOR, 3.75 [95% CI, 1.30 -10.83]) both had a statistically significant association with symptomatic VVC.
Yeast morphology and symptomatic VVC. Compared with visits at which samples were obtained that showed only budding yeast forms on microscopy, there was an increased likelihood of identifying symptomatic VVC during visits at which samples were obtained that showed pseudohyphae (OR, 2.63 [95% CI, 1.24 -5.57]). Because the symptom of abnormal vaginal discharge may be less specific for the diagnosis of symptomatic VVC [19] , we repeated this analysis after excluding the 6 visits at which women reported abnormal vaginal discharge as the only symptom of VVC. Once again, the presence of pseudohyphae was associated with an increased risk of symptomatic VVC (OR, 2.42 [95% CI, 1.09 -5.41]).
DISCUSSION
This prospective cohort study offers insight into the dynamic interrelationships between vaginal bacterial flora, VVC, and symptomatic VVC. In particular, these data provide strong evidence contradicting the hypothesis that vaginal colonization with Lactobacillus reduces the risk of VVC. Indeed, the opposite may be true. We found that BV was associated with a substantial reduction in the risk of VVC. Lactobacillus colonization, on the other hand, was associated with a nearly 4-fold increase in the likelihood of symptomatic VVC.
Two earlier prospective studies have suggested that vaginal Lactobacillus colonization is associated with an increased risk of vaginal yeast colonization (as identified by yeast culture) and VVC (as identified by wet preparation or potassium hydroxide preparation) [20, 21] . Neither study evaluated whether these associations were independent of the presence of BV. Our present study demonstrated a statistically nonsignificant positive association between Lactobacillus colonization and VVC. However, our results suggest that BV, which is characterized by the presence of a complex polymicrobial bacterial community that includes high concentrations of anaerobic bacteria [22] , may play a more important role in mediating the risk of VVC than does Lactobacillus.
Although neither of the earlier studies of vaginal yeast colonization and VVC evaluated the association between Lactobacillus and symptomatic VVC, one longitudinal study sought to test the hypothesis that women colonized by lactobacilli have a lower rate of vaginal infections [23] . That study, conducted in a United States population, demonstrated that women who were colonized with non-H 2 O 2 -producing Lactobacillus or not colonized with Lactobacillus (i.e., women with or at risk of BV) were at lower risk of symptomatic vaginal yeast infections, compared with women who were colonized with H 2 O 2 -producing Lactobacillus, although these results were not statistically significant. Addressing their primary hypothesis, the authors concluded that the absence of lactobacilli did not increase the risk of VVC. Our present findings go a step further, showing that the likelihood of symptomatic VVC may be significantly increased when lactobacilli are present.
Several mechanisms may contribute to lower rates of VVC among women with BV, including production of bacterial toxins and competition for available energy sources, micronutrients, and mucosal attachment sites. Interestingly, in women who develop VVC despite having concurrent BV, low vaginal levels of interleukin-8 could attenuate the aggressive, neutrophil-predominant immune response that appears to be important in the pathogenesis of symptomatic VVC [24, 25] . In contrast, vaginal lactobacilli may produce an immunostimulatory effect, increasing interleukin-8 production by the vaginal mucosa [24] .
The risk of symptomatic VVC after treatment with metronidazole has been recognized for nearly 4 decades [26] . In the present study (table 3) , we observed a trend for a Ͼ6-fold increase in the likelihood of symptomatic VVC following treatment with metronidazole. This finding parallels the results of recent studies quantifying this risk in a variety of settings. A randomized trial of suppressive topical metronidazole in United States women with recurrent BV demonstrated a significantly higher rate of vaginal candidiasis among women assigned to the active treatment, compared with those in the placebo arm (43% vs. 21%) [27] . Likewise, symptoms of VVC were reported by nearly half the women treated with oral metronidazole in a prospective cohort study of Australian women [28] . Metronidazole could increase the risk of symptomatic VVC by reducing the population of BV-associated bacteria or by promoting Lactobacillus colonization [13] . Systemic administration of metronidazole could also promote vaginal candidiasis by increasing the concentration of Candida in the gut [29] , although published data addressing this possibility are limited.
In this study, we defined symptomatic VVC as the presence of yeast forms on wet mounts or potassium hydroxide preparations of vaginal secretions in combination with 1 signs and symptoms, including vulvitis, vulvovaginal pruritis, and/or abnormal vaginal discharge. This definition reflects the signs and symptoms most commonly identified in women with symptomatic VVC [30, 31] . While vulvovaginal pruritis without discharge is the most specific clinical presentation, it correctly predicts VVC in only 38% of cases [19] . Thus, we felt that a broader definition of symptoms was preferable for our analyses. We acknowledge that, during visits at which both BV and VVC are identified, the symptom of abnormal vaginal discharge could be related to either condition. To address this possibility, we repeated our analyses after excluding visits at which both BV and VVC were identified. The observed relationships between yeast colonization, Lactobacillus colonization, and symptomatic VVC were further strengthened in these analyses.
It has been suggested that the presence of pseudohyphae is associated with a higher likelihood of symptomatic VVC. In a rat experimental model of VVC, the production of hyphal elements appeared to be an important but nonessential virulence factor [32] . However, there are limited supporting data from human studies [33] . In our current investigation, for visits at which samples that yielded yeast were obtained, we found that the likelihood of symptomatic VVC was Ͼ2-fold greater when pseudohyphae were present, compared to visits at which samples were obtained that showed only budding yeast forms. This modest but statistically significant association may reflect the fact that although hyphal forms are more invasive, both blastoconidia and pseudohyphae are capable of destroying superficial epithelial cells by direct invasion [34] .
There were limitations to this study. Because yeast culture was not performed, we were not able to identify women who had yeast colonization (i.e., positive culture results with negative microscopy results) [12] . Some cases of symptomatic VVC could have been missed by microscopy alone [35] . False-positive results may also occur when microscopy is used to identify yeast, particularly in cases where blastoconidia are observed in the absence of hyphal elements.
Although we were able to perform culture for Lactobacillus, there are limitations to this approach. Some species, such as L. iners, may be common in African women [36] but would not be detected by culture on Rogosa agar. It is notable that the overall rate at which Lactobacillus was isolated in this population was much lower than that in western populations [17, 23] . We have previously shown that the practice of vaginal washing, which was highly prevalent among these women, was associated with a statistically significant reduction in the isolation of Lactobacillus species [37] . This practice may have contributed to the low rate of Lactobacillus isolation in the present study. Finally, in our analyses of the effects of metronidazole and antifungals on VVC, there is the possibility for confounding by indication. For example, antifungals might be administered for symptomatic VVC, but the condition tends to recur, which could contribute to a positive association between antifungal use and VVC. Nonetheless, these prospectively collected data provide new insights into the relationships between vaginal bacterial flora, VVC, and symptomatic VVC.
Both VVC and BV have been associated with an increased risk of HIV-1 infection [2, 3, 6, 38] . In contrast, vaginal colonization with H 2 O 2 -producing Lactobacillus has been associated with a lower risk of acquiring HIV-1 [20] . Taken together, the available data suggest that the optimal vaginal flora for minimizing women's HIV-1 infection risk may include H 2 O 2 -producing Lactobacillus in the absence of VVC. Our findings suggest that simply promoting Lactobacillus colonization may not reduce VVC. This insight will enhance our ability to improve vaginal health and the potential to develop strategies for reducing the risk of HIV-1 infection through vaginal health interventions.
